Rapid Micro Biosystems (RPID)
(Delayed Data from NSDQ)
$0.84 USD
+0.01 (1.07%)
Updated Sep 18, 2024 03:59 PM ET
After-Market: $0.84 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.84 USD
+0.01 (1.07%)
Updated Sep 18, 2024 03:59 PM ET
After-Market: $0.84 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum C VGM
Zacks News
What's in Store for Cooper Companies (COO) in Q3 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter results are likely to reflect segmental strength.
Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of -3.57% and 10.03%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of -6.90% and 0.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Edwards Lifesciences (EW) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 3.13% and 1.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Rapid Micro Biosystems, Inc. (RPID) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of 3.12% and 11.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of 8.33% and 18.39%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Alphatec (ATEC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alphatec (ATEC) delivered earnings and revenue surprises of -43.33% and 6.12%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of -1.47% and 0.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Rapid Micro Biosystems, Inc. (RPID) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Rapid Micro Biosystems, Inc. (RPID) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of 11.11% and 15.93%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Alphatec (ATEC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alphatec (ATEC) delivered earnings and revenue surprises of -25% and 0.93%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Rapid Micro Biosystems, Inc. (RPID) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of -2.63% and 1.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of 50% and 1.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Inari Medical, Inc. (NARI) Soars 6.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Inari Medical, Inc. (NARI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Rapid Micro Biosystems, Inc. (RPID) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of -2.70% and 20.43%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 21.05% and 6.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Nevro (NVRO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of 12.68% and 1.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Idexx Laboratories (IDXX) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 5.39% and 1.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of 11.43% and 24.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech (FBIO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of -20% and 17.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ConforMIS (CFMS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ConforMIS (CFMS) delivered earnings and revenue surprises of -12.50% and 1.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Think Rapid Micro Biosystems, Inc. (RPID) Could Surge 310%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Rapid Micro Biosystems, Inc. (RPID) points to a 309.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does Rapid Micro Biosystems, Inc. (RPID) Have the Potential to Rally 215% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 214.9% upside potential for Rapid Micro Biosystems, Inc. (RPID). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.